44 completed, 7 unknown, 4 terminated, 2 recruiting. 19 Phase 2, 12 Phase 1, 9 Not applicable, 8 Phase 4, 5 Early Phase 1.
Follow Dextroamphetamine: new trials by email Literature Review of Dextroamphetamine trials Research Report on Dextroamphetamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder 3,4-methylenedioxymethamphetamine, d-amphetamine, Therapy - Post Traumatic Stress Disorder | Phase 2 | Recruiting | Stephen Robert Marder | 40 | 2025-03-01 | 2026-08-19 |
| The Difference in the Mechanism of Action Between Two Brands of Dexamfetamine in Adults With ADHD Dexamfetamine - Attention Deficit Disorder With Hyperactivity | Not applicable | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 | 2023-04-14 | 2025-02-18 |
| [C-11]NPA PET-amphetamine in Cocaine Use Disorders Baseline [C-11]NPA PET Scan, d-amphetamine, Post-amphetamine [C-11]NPA PET Scan - Cocaine Use Disorder | Early Phase 1 | Recruiting | Rajesh Narendran | 30 | 2021-01-31 | 2026-07-06 |
| Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia d-amphetamine, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 | Completed | University of California, San Diego | 68 | 2020-11-09 | 2025-12-17 |
| Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR) ADAIR 10 mg IR tablets, d-amphetamine sulfate, Placebo - ADHD, Narcolepsy | Phase 1 | Completed | Vallon Pharmaceuticals, Inc. | 55 | 2020-10-05 | 2021-12-29 |
| Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate - Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder | Completed | Nemours Children's Clinic | 70 | 2020-09-13 | 2022-12-13 | |
| 8 Week Multi-site Study of MYDAYIS® for Bipolar Depression Mydayis Extended-Release Capsule, Placebo - Bipolar Depression | Phase 2 | Completed | Mayo Clinic | 74 | 2020-07-17 | 2025-08-12 |
| A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine Methylphenidate, Lisdexamfetamine, Atomoxetine - Attention Deficit Disorder With Hyperactivity | Completed | Janssen Research & Development, LLC | 430000 | 2019-10-09 | 2025-06-25 | |
| Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia NPA radiotracer, Raclopride radiotracer, Dextroamphetamine - Schizophrenia | Withdrawn | NYU Langone Health | 2019-07-01 | 2020-05-29 | ||
| Effect of D-amphetamine on Reward Functioning 10 mg d-amphetamine, 20mg d-amphetamine, Placebo - Anhedonia | Phase 1 | Completed | The University of Texas Health Science Center, Houston | 68 | 2018-01-24 | 2020-11-05 |
| Brain Mechanisms in Young Adults d-amphetamine, [C-11]NPA - Cocaine-Related Disorders | Early Phase 1 | Completed | Gale Richardson | 13 | 2018-01-24 | 2020-09-03 |
| Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and Release Dextroamphetamine Sulfate - Schizophrenia, Psychosis | Not applicable | Unknown | Medical University of Vienna | 22 | 2018-01-01 | 2018-04-19 |
| A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users Tozadenant, Placebo oral tablet, d-amphetamine - Abuse Potential | Phase 1 | Terminated | Biotie Therapies Inc. | 26 | 2017-09-18 | 2018-08-13 |
| Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD Magnetic Resonance Imaging (MRI), PHNO, calcitriol - ADHD | Phase 1 | Completed | Yale University | 24 | 2017-08-15 | 2024-03-19 |
| Differential Responses to Drugs and Sweet Tastes Placebo oral capsule, d-amphetamine 10 mg oral capsule, d-amphetamine 20 mg oral capsule - Bipolar II Disorder | Phase 1 | Completed | University of Chicago | 93 | 2017-02-09 | 2023-02-22 |
| Targeting Anhedonia in Cocaine Use Disorder d-amphetamine, Contingency management, Placebo (for d-amphetamine) - Cocaine-Related Disorders, Anhedonia | Phase 2 | Completed | University of Illinois at Chicago | 57 | 2017-02-01 | 2024-08-09 |
| Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing LSD, MDMA, Amphetamine - Healthy | Early Phase 1 | Completed | University Hospital, Basel, Switzerland | 28 | 2017-02-01 | 2018-10-15 |
| Bariatric Surgery and Pharmacokinetics of Dexamphetamine Dexamphetamine - Obesity, Morbid | Completed | Norwegian University of Science and Technology | 12 | 2016-11-02 | 2025-06-27 | |
| Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots Dexamphetamine - Cocaine Addiction | Early Phase 1 | Completed | The Netherlands Cancer Institute | 12 | 2016-11-01 | 2017-06-02 |
| A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD HLD100 - Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Completed | Ironshore Pharmaceuticals and Development, Inc | 22 | 2016-08-01 | 2021-07-19 |
Showing 20 of 59. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (18) · Cocaine-Related Disorders (12) · Schizophrenia (4) · Substance-Related Disorders (4) · Psychotic Disorders (3) · Anhedonia (2) · Bipolar Disorder (2) · Conduct Disorder (2) · Opioid-Related Disorders (2) · Oppositional Defiant Disorder (2) · Stroke (2) · Tobacco Use Disorder (2) · Aggression (1) · Alcoholism (1) · Alzheimer Disease (1)
The University of Texas Health Science Center, Houston (6) · McGill University Health Centre/Research Institute of the McGill University Health Centre (3) · National Institute on Drug Abuse (NIDA) (3) · University of California, San Diego (3) · Yale University (3) · Massachusetts General Hospital (2) · University Hospital, Basel, Switzerland (2) · University of Chicago (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Biotie Therapies Inc. (1) · California Pacific Medical Center Research Institute (1) · Centre for Addiction and Mental Health (1) · Duke University (1) · Gale Richardson (1) · Ironshore Pharmaceuticals and Development, Inc (1)
United States (43) · Canada (7) · Netherlands (3) · Norway (2) · Switzerland (2) · Austria (1)
John Grabowski, Ph.D. (4) · Lily Hechtman, MD, FRCPC (4) · Joseph C. Blader, PhD, MSc (2) · Joy M. Schmitz, PhD (2) · Matthias E Liechti, MD, MAS (2) · Alex Odermatt, Dr. (1) · Ana Weidenauer, MD (1) · Angela L Stotts, PhD (1) · Ann Childress, MD (1) · Arne K. Henriksen, Phd (1) · Craig R Rush, Ph.D. (1) · Craig Surman, MD (1) · Daniela Lobo, MD, Ph.D. (1) · David Zald, Zald (1) · Frederick G Moeller, MD (1)
PMID 24290461, PMID 26745211, PMID 18591575, PMID 19573497, PMID 19884222, PMID 21356232, PMID 22969732, PMID 23659360, PMID 24666268, PMID 24972362, PMID 26513587, PMID 28936175, PMID 29511807, PMID 30167675, PMID 32007604, PMID 35020462, PMID 36913518, PMID 36919514, PMID 37339441
P50DA009262 (3), R01DA026472 (2), 2015 (1), K02DA031750 (1), K23MH064975 (1), M01RR010710 (1), P50CA196530 (1), P50DA018179 (1), R01AT010508 (1), R01DA016305 (1), R01DA021155 (1), R01DA026761 (1), R01MH092793 (1), R25MH071584 (1)